closer schreef op 29 april 2020 19:05:
uit The Guardian (liveblog 18:26):
No clinical benefits from remdesivir, study findsTreating coronavirus patients with the antiviral drug remdesivir showed no “significant clinical benefits” in the first randomised trial of its kind, according to research released on Wednesday, AFP reports.
In a study among more than 200 Covid-19 patients in Wuhan, China, published in The Lancet, doctors found no positive effects of administering the drug compared with a control group of adults.
The findings were released after US pharmaceutical giant Gilead, which makes remdesivir, said a separate large-scale trial with the drug had showed positive results.“Unfortunately, our trial found that while safe and adequately tolerated, remdesivir did not provide significant benefits over placebo,” said Bin Cao from China-Japan Friendship Hospital and Capital Medical University in China, who led the research.
“This is not the outcome we hoped for.”